Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust Sells 2,408 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWSTGet Free Report) CEO Emily M. Leproust sold 2,408 shares of the company’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $51.33, for a total value of $123,602.64. Following the completion of the transaction, the chief executive officer now directly owns 507,578 shares in the company, valued at approximately $26,053,978.74. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Twist Bioscience Stock Down 0.9 %

Shares of NASDAQ:TWST opened at $50.01 on Tuesday. The firm has a 50 day moving average of $38.32 and a 200 day moving average of $35.86. The company has a market capitalization of $2.91 billion, a price-to-earnings ratio of -14.88 and a beta of 1.78. Twist Bioscience Co. has a 52 week low of $14.42 and a 52 week high of $54.13.

Twist Bioscience (NASDAQ:TWSTGet Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The firm had revenue of $75.30 million during the quarter, compared to analyst estimates of $70.70 million. During the same period in the previous year, the company posted ($1.06) EPS. The business’s revenue for the quarter was up 25.1% compared to the same quarter last year. On average, sell-side analysts expect that Twist Bioscience Co. will post -3.08 EPS for the current year.

Institutional Trading of Twist Bioscience

Several hedge funds have recently modified their holdings of TWST. Castleark Management LLC grew its position in shares of Twist Bioscience by 11.8% in the 1st quarter. Castleark Management LLC now owns 146,630 shares of the company’s stock worth $5,031,000 after buying an additional 15,470 shares during the last quarter. Bayesian Capital Management LP grew its holdings in Twist Bioscience by 42.7% in the first quarter. Bayesian Capital Management LP now owns 14,546 shares of the company’s stock worth $499,000 after purchasing an additional 4,352 shares during the last quarter. Silvercrest Asset Management Group LLC grew its holdings in Twist Bioscience by 38.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after purchasing an additional 37,376 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Twist Bioscience by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 32,127 shares of the company’s stock worth $1,103,000 after purchasing an additional 2,292 shares in the last quarter. Finally, Magnetar Financial LLC acquired a new stake in shares of Twist Bioscience in the 1st quarter worth $389,000.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on TWST. Guggenheim began coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 price target on the stock. Evercore ISI raised their target price on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Barclays boosted their price target on Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Robert W. Baird lifted their target price on Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Finally, Scotiabank increased their price target on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday, May 6th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $44.00.

Check Out Our Latest Analysis on Twist Bioscience

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Featured Stories

Insider Buying and Selling by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.